Malignant struma ovarii harboring a unique NRAS mutation

Case report and review of the literature

Carlo Gobitti, Alessandro Sindoni, Chiara Bampo, Tanja Baresic, Giorgio Giorda, Lara Alessandrini, Vincenzo Canzonieri, Giovanni Franchin, Eugenio Borsatti

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Struma ovarii (SO), a rare tumor containing at least 50% of thyroid tissue, represents approximately 5% of all ovarian teratomas; its malignant transformation rate is reported to occur in up to 10% of cases and metastases occur in about 5-6% of them. We describe a 36-year old woman who underwent laparoscopic left annessectomy two years earlier because of an ovarian cyst. Follow-up imaging revealed a right adnexal mass, ascitis and peritoneal nodes that were diagnosed as comprising a malignant SO with peritoneal secondary localizations at histopathology performed after intervention. Restaging with18F-FDG-PET/CT scan, abdominal CT and ultrasonography showed abnormalities in the perihepatic region and presacral space and left hypochondrium localizations. The patient underwent thyroidectomy, hepatic nodulectomy and cytoreductive peritonectomy: histopathological examination did not show any malignant disease in the thyroid and confirmed the presence of peritoneal localizations due to malignant SO; molecular analysis detected NRAS Q61K mutation in exon 3, whereas no mutations were identified on the BRAF gene. The patient underwent radioiodine treatment: serum Tg was decreased at first follow-up after three months of131I-therapy. We believe that our case raises some interesting considerations. First, pathologists should be aware of this entity and should check for the presence of point mutations suggesting an aggressive disease behavior, which could be beneficial for an optimal therapeutic approach. Second, although most of the knowledge in this field comes from case reports, efforts should be made to standardize the management of patients affected by malignant SO, including use of practice guidelines.

Original languageEnglish
Pages (from-to)322-327
Number of pages6
JournalHormones
Volume16
Issue number3
DOIs
Publication statusPublished - Jul 1 2017

Fingerprint

Struma Ovarii
Mutation
Ovarian Cysts
Thyroid Diseases
Thyroidectomy
Practice Guidelines
Point Mutation
Exons
Ultrasonography
Thyroid Gland
Therapeutics
Neoplasm Metastasis
Liver
Serum
Genes
Neoplasms

Keywords

  • I-131
  • Malignant struma ovarii
  • Papillary thyroid carcinoma
  • Radioiodine
  • Treatment

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism

Cite this

Malignant struma ovarii harboring a unique NRAS mutation : Case report and review of the literature. / Gobitti, Carlo; Sindoni, Alessandro; Bampo, Chiara; Baresic, Tanja; Giorda, Giorgio; Alessandrini, Lara; Canzonieri, Vincenzo; Franchin, Giovanni; Borsatti, Eugenio.

In: Hormones, Vol. 16, No. 3, 01.07.2017, p. 322-327.

Research output: Contribution to journalArticle

@article{22b5bf3d515848218d964e2c1be1fcfb,
title = "Malignant struma ovarii harboring a unique NRAS mutation: Case report and review of the literature",
abstract = "Struma ovarii (SO), a rare tumor containing at least 50{\%} of thyroid tissue, represents approximately 5{\%} of all ovarian teratomas; its malignant transformation rate is reported to occur in up to 10{\%} of cases and metastases occur in about 5-6{\%} of them. We describe a 36-year old woman who underwent laparoscopic left annessectomy two years earlier because of an ovarian cyst. Follow-up imaging revealed a right adnexal mass, ascitis and peritoneal nodes that were diagnosed as comprising a malignant SO with peritoneal secondary localizations at histopathology performed after intervention. Restaging with18F-FDG-PET/CT scan, abdominal CT and ultrasonography showed abnormalities in the perihepatic region and presacral space and left hypochondrium localizations. The patient underwent thyroidectomy, hepatic nodulectomy and cytoreductive peritonectomy: histopathological examination did not show any malignant disease in the thyroid and confirmed the presence of peritoneal localizations due to malignant SO; molecular analysis detected NRAS Q61K mutation in exon 3, whereas no mutations were identified on the BRAF gene. The patient underwent radioiodine treatment: serum Tg was decreased at first follow-up after three months of131I-therapy. We believe that our case raises some interesting considerations. First, pathologists should be aware of this entity and should check for the presence of point mutations suggesting an aggressive disease behavior, which could be beneficial for an optimal therapeutic approach. Second, although most of the knowledge in this field comes from case reports, efforts should be made to standardize the management of patients affected by malignant SO, including use of practice guidelines.",
keywords = "I-131, Malignant struma ovarii, Papillary thyroid carcinoma, Radioiodine, Treatment",
author = "Carlo Gobitti and Alessandro Sindoni and Chiara Bampo and Tanja Baresic and Giorgio Giorda and Lara Alessandrini and Vincenzo Canzonieri and Giovanni Franchin and Eugenio Borsatti",
year = "2017",
month = "7",
day = "1",
doi = "10.14310/horm.2002.1750",
language = "English",
volume = "16",
pages = "322--327",
journal = "Hormones",
issn = "1109-3099",
publisher = "Hellenic Endocrine Society",
number = "3",

}

TY - JOUR

T1 - Malignant struma ovarii harboring a unique NRAS mutation

T2 - Case report and review of the literature

AU - Gobitti, Carlo

AU - Sindoni, Alessandro

AU - Bampo, Chiara

AU - Baresic, Tanja

AU - Giorda, Giorgio

AU - Alessandrini, Lara

AU - Canzonieri, Vincenzo

AU - Franchin, Giovanni

AU - Borsatti, Eugenio

PY - 2017/7/1

Y1 - 2017/7/1

N2 - Struma ovarii (SO), a rare tumor containing at least 50% of thyroid tissue, represents approximately 5% of all ovarian teratomas; its malignant transformation rate is reported to occur in up to 10% of cases and metastases occur in about 5-6% of them. We describe a 36-year old woman who underwent laparoscopic left annessectomy two years earlier because of an ovarian cyst. Follow-up imaging revealed a right adnexal mass, ascitis and peritoneal nodes that were diagnosed as comprising a malignant SO with peritoneal secondary localizations at histopathology performed after intervention. Restaging with18F-FDG-PET/CT scan, abdominal CT and ultrasonography showed abnormalities in the perihepatic region and presacral space and left hypochondrium localizations. The patient underwent thyroidectomy, hepatic nodulectomy and cytoreductive peritonectomy: histopathological examination did not show any malignant disease in the thyroid and confirmed the presence of peritoneal localizations due to malignant SO; molecular analysis detected NRAS Q61K mutation in exon 3, whereas no mutations were identified on the BRAF gene. The patient underwent radioiodine treatment: serum Tg was decreased at first follow-up after three months of131I-therapy. We believe that our case raises some interesting considerations. First, pathologists should be aware of this entity and should check for the presence of point mutations suggesting an aggressive disease behavior, which could be beneficial for an optimal therapeutic approach. Second, although most of the knowledge in this field comes from case reports, efforts should be made to standardize the management of patients affected by malignant SO, including use of practice guidelines.

AB - Struma ovarii (SO), a rare tumor containing at least 50% of thyroid tissue, represents approximately 5% of all ovarian teratomas; its malignant transformation rate is reported to occur in up to 10% of cases and metastases occur in about 5-6% of them. We describe a 36-year old woman who underwent laparoscopic left annessectomy two years earlier because of an ovarian cyst. Follow-up imaging revealed a right adnexal mass, ascitis and peritoneal nodes that were diagnosed as comprising a malignant SO with peritoneal secondary localizations at histopathology performed after intervention. Restaging with18F-FDG-PET/CT scan, abdominal CT and ultrasonography showed abnormalities in the perihepatic region and presacral space and left hypochondrium localizations. The patient underwent thyroidectomy, hepatic nodulectomy and cytoreductive peritonectomy: histopathological examination did not show any malignant disease in the thyroid and confirmed the presence of peritoneal localizations due to malignant SO; molecular analysis detected NRAS Q61K mutation in exon 3, whereas no mutations were identified on the BRAF gene. The patient underwent radioiodine treatment: serum Tg was decreased at first follow-up after three months of131I-therapy. We believe that our case raises some interesting considerations. First, pathologists should be aware of this entity and should check for the presence of point mutations suggesting an aggressive disease behavior, which could be beneficial for an optimal therapeutic approach. Second, although most of the knowledge in this field comes from case reports, efforts should be made to standardize the management of patients affected by malignant SO, including use of practice guidelines.

KW - I-131

KW - Malignant struma ovarii

KW - Papillary thyroid carcinoma

KW - Radioiodine

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=85039713954&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85039713954&partnerID=8YFLogxK

U2 - 10.14310/horm.2002.1750

DO - 10.14310/horm.2002.1750

M3 - Article

VL - 16

SP - 322

EP - 327

JO - Hormones

JF - Hormones

SN - 1109-3099

IS - 3

ER -